World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
161
Citations
117184
World Ranking
739
National Ranking
420

Mark G. Kris publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Mark G. Kris sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 769 publications — 85th percentile

85% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Mark G. Kris D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Mark G. Kris sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 161 D-Index — 96th percentile

96% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Mark G. Kris is affiliated with Memorial Sloan Kettering Cancer Center in the United States. Their research primarily focuses on medicine, with a strong emphasis on pulmonary and respiratory medicine, oncology, and cancer research. Additional areas of study include molecular biology and radiology, nuclear medicine, and imaging.

Their main topics of research cover several aspects of lung cancer, including treatments, mutations, diagnosis, and overall research studies. Kris also contributes to cancer genomics and diagnostics, as well as cancer immunotherapy and biomarkers. Radiomics and machine learning applications in medical imaging and studies related to colorectal cancer treatment are also among their interests.

Mark G. Kris frequently publishes in several medical and oncology journals. The most common venues for their work include:

  • Journal of Clinical Oncology
  • Journal of Thoracic Oncology
  • Clinical Cancer Research
  • JCO Precision Oncology
  • Annals of Oncology

The scientist collaborates regularly with other researchers in their field. Notable co-authors include Charles M. Rudin, Jamie E. Chaft, Helena A. Yu, Gregory J. Riely, and Marc Ladanyi, reflecting active participation in collaborative research networks.

Significant recent publications by Mark G. Kris or closely related to their research interests include:

  • IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy, 2020, Journal of Thoracic Oncology
  • Antiemetics: ASCO Guideline Update, 2020, Journal of Clinical Oncology
  • Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer, 2020, Clinical Cancer Research
  • Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer, 2021, Nature Reviews Clinical Oncology
  • HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers, 2020, Cancer Discovery

Best Publications

  • EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

    William Pao;Vincent Miller;Maureen Zakowski;Jennifer Doherty

  • Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

    William Pao;Vincent A. Miller;Katerina A Politi;Gregory J. Riely

  • Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients with Non-Small Cell Lung Cancer: A Randomized Trial

    Mark G. Kris;Ronald B. Natale;Roy S. Herbst;Thomas J. Lynch

  • Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

    Helena A. Yu;Maria E. Arcila;Natasha Rekhtman;Camelia S. Sima

  • Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial.

    Ethan Basch;Allison M. Deal;Mark G. Kris;Howard I. Scher

  • Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens

    Frank V. Fossella;Russell DeVore;Ronald N. Kerr;Jeffrey Crawford

  • KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

    William Pao;Theresa Y Wang;Gregory J Riely;Vincent A Miller

  • Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment

    Ethan Martin Basch;Allison M. Deal;Amylou C. Dueck;Howard I. Scher

  • TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer

    Roy S. Herbst;Diane Prager;Robert Hermann;Lou Fehrenbacher

  • Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer

    Jeffrey Crawford;Howard Ozer;Ronald Stoller;David H Johnson

  • Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

    Mark G. Kris;Bruce E. Johnson;Lynne D. Berry;David J. Kwiatkowski

  • Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.

    Hira Rizvi;Francisco Sanchez-Vega;Konnor La;Walid Chatila

  • Characterizing the cancer genome in lung adenocarcinoma

    Barbara A. Weir;Barbara A. Weir;Michele S. Woo;Gad Getz;Sven Perner;Sven Perner

  • Non–Small Cell Lung Cancer

    David S. Ettinger;Wallace Akerley;Gerold Bepler;Andrew Chang

  • Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study.

    Kerby Shedden;Jeremy M.G. Taylor;Steven A. Enkemann;Ming Sound Tsao

  • Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.

    George D. Demetri;Mark Kris;James Wade;Laurent Degos

  • ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial

    Malcolm R Ranson;Lisa A Hammond;David R Ferry;Mark Kris

  • Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases

    Akihiko Yoshizawa;Noriko Motoi;Noriko Motoi;Gregory J Riely;Cami S Sima

  • Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update

    Paul J. Hesketh;Mark G. Kris;Ethan Martin Basch;Kari Bohlke

  • Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non-Small Cell Lung Cancer

    Mark G. Kris;Ronald B. Natale;Roy S. Herbst;Diane Prager

Frequent Co-Authors

Gregory J. Riely
Gregory J. Riely Memorial Sloan Kettering Cancer Center
Marc Ladanyi
Marc Ladanyi Memorial Sloan Kettering Cancer Center
Charles M. Rudin
Charles M. Rudin Memorial Sloan Kettering Cancer Center
Maria E. Arcila
Maria E. Arcila Memorial Sloan Kettering Cancer Center
William Pao
William Pao Roche (United States)
Valerie W. Rusch
Valerie W. Rusch Memorial Sloan Kettering Cancer Center
Maureen F. Zakowski
Maureen F. Zakowski Icahn School of Medicine at Mount Sinai
Naiyer A. Rizvi
Naiyer A. Rizvi Columbia University Medical Center
Matthew D. Hellmann
Matthew D. Hellmann Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

As interest grows in studying Medicine in the USA, many students are exploring related online degrees that complement traditional medical pathways. Flexible online options make it easier to balance education, work, and personal commitments while pursuing healthcare careers.

If you’re interested in mental health, psych np online programs offer a fast-track route to becoming a Psychiatric Mental Health Nurse Practitioner. This advanced nursing role is in high demand and provides essential mental health care across various settings.

For those drawn to healthcare leadership, the best online mha programs as well as the cheapest master's in healthcare administration provide pathways into management roles. These programs focus on healthcare operations, policy, and finance, opening doors to administrative positions in hospitals and clinics.

Those seeking the highest levels of clinical expertise may consider the most affordable online dnp programs. Earning a Doctor of Nursing Practice (DNP) prepares graduates for leadership roles, advanced practice, and evidence-based patient care.

Online healthcare degrees not only offer convenience, but can also help reduce educational costs, making advanced medical careers more accessible than ever.

Best Scientists Citing Mark G. Kris

Trending Scientists

Recently Published Articles